BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32908255)

  • 41. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
    Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.
    Ma ES; Wang CL; Wong AT; Choy G; Chan TL
    Mol Cytogenet; 2016; 9():63. PubMed ID: 27532015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
    Chang H; Yeung J; Xu W; Ning Y; Patterson B
    Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
    Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
    Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.
    Yamamoto K; Yakushijin K; Ito M; Goto H; Higashime A; Kajimoto K; Hayashi Y; Matsuoka H; Minami H
    Cancer Genet; 2020 Apr; 242():35-40. PubMed ID: 32035866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
    Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
    Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
    Gao X; Li C; Zhang R; Yang R; Qu X; Qiu H; Xu J; Lu H; Li J; Chen L
    Med Oncol; 2012 Sep; 29(3):2200-6. PubMed ID: 21611837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma].
    Wang YF; Wang H; Xi LY; Liu Y; Dong F; Wang JJ; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1352-6. PubMed ID: 26524036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
    Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 55. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical and experimental study of a multiple myeloma case with low hypodiploidy].
    Bai SX; Pan JL; Xue YQ; Chen SN; Wu YF; Wang Y; Zhang J; Shen J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Jun; 29(3):343-6. PubMed ID: 22678804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
    Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
    Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
    You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
    Front Oncol; 2022; 12():938392. PubMed ID: 36276097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
    Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
    Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
    Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.